PsychoGenics is uniquely positioned to support preclinical psychedelic research involving DEA schedule 1 drugs. We’ve established the necessary secure storage infrastructure, custody protocols and procedures to secure DEA licenses for your studies with schedule 1 compounds.
Full Support for Preclinical Psychedelics Studies
From psilocybin and MDMA analogs to CBD and beyond, our capabilities enable in-depth exploration of these promising therapeutic agents. With our experience testing various psychedelic classes in rodent disease models, we can provide valuable data upon request.
No matter the class, we bring our broad array of expert research support services to meet your preclinical psychedelics research needs.
Explore our emerging therapies capabilities: